January 5, 2023 08:47 PM ESTUpdated 06:41 AM
Deals
Pharma

Fate and J&J end deal that once promised $3B in mile­stones; biotech cuts staff

Drew Armstrong

Executive Editor

Fate Ther­a­peu­tics said that it agreed with John­son & John­son to ter­mi­nate a part­ner­ship they struck in 2020 to de­vel­op can­cer im­munother­a­pies, a deal that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times